HUP0401619A2 - Fenilanolamin-származékok, eljárás előállításukra, és az ezeket tartalmazó gyógyszerkészítmények - Google Patents
Fenilanolamin-származékok, eljárás előállításukra, és az ezeket tartalmazó gyógyszerkészítményekInfo
- Publication number
- HUP0401619A2 HUP0401619A2 HU0401619A HUP0401619A HUP0401619A2 HU P0401619 A2 HUP0401619 A2 HU P0401619A2 HU 0401619 A HU0401619 A HU 0401619A HU P0401619 A HUP0401619 A HU P0401619A HU P0401619 A2 HUP0401619 A2 HU P0401619A2
- Authority
- HU
- Hungary
- Prior art keywords
- 6alkyl
- aryl
- heteroaryl
- xnr8c
- group
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- ULSIYEODSMZIPX-UHFFFAOYSA-N phenylethanolamine Chemical class NCC(O)C1=CC=CC=C1 ULSIYEODSMZIPX-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 18
- 125000003118 aryl group Chemical group 0.000 abstract 10
- 125000001072 heteroaryl group Chemical group 0.000 abstract 6
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 5
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical group 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- -1 Cl-6alkyl Chemical group 0.000 abstract 1
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/76—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups bound to carbon atoms of six-membered aromatic rings and etherified hydroxy groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/75—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/32—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C271/38—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/40—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HUS1400025C HUS1400025I1 (hu) | 2001-09-14 | 2014-04-24 | Feniletanolamin-származékok és az ezeket tartalmazó gyógyszerek |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0122201A GB0122201D0 (en) | 2001-09-14 | 2001-09-14 | Medicinal compounds |
GB0126997A GB0126997D0 (en) | 2001-11-09 | 2001-11-09 | Medicinal Compounds |
PCT/GB2002/004140 WO2003024439A1 (en) | 2001-09-14 | 2002-09-11 | Phenethanolamine derivatives for treatment of respiratory diseases |
Publications (3)
Publication Number | Publication Date |
---|---|
HUP0401619A2 true HUP0401619A2 (hu) | 2004-11-29 |
HUP0401619A3 HUP0401619A3 (en) | 2008-03-28 |
HU228508B1 HU228508B1 (en) | 2013-03-28 |
Family
ID=26246542
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0401619A HU228508B1 (en) | 2001-09-14 | 2002-09-11 | Phenethanolamine derivatives and pharmaceutical composition containing them |
HUS1400025C HUS1400025I1 (hu) | 2001-09-14 | 2014-04-24 | Feniletanolamin-származékok és az ezeket tartalmazó gyógyszerek |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUS1400025C HUS1400025I1 (hu) | 2001-09-14 | 2014-04-24 | Feniletanolamin-származékok és az ezeket tartalmazó gyógyszerek |
Country Status (31)
Country | Link |
---|---|
US (6) | USRE44874E1 (hu) |
EP (2) | EP2042168B1 (hu) |
JP (1) | JP4191034B2 (hu) |
KR (2) | KR20090057477A (hu) |
CN (3) | CN101701006B (hu) |
AR (2) | AR036874A1 (hu) |
AT (1) | ATE417606T1 (hu) |
AU (1) | AU2002326026B2 (hu) |
BE (1) | BE2014C026I2 (hu) |
BR (1) | BRPI0212455B8 (hu) |
CA (1) | CA2458534C (hu) |
CO (1) | CO5560552A2 (hu) |
CY (3) | CY1109422T1 (hu) |
DE (1) | DE60230425D1 (hu) |
DK (2) | DK2042168T3 (hu) |
ES (2) | ES2438985T3 (hu) |
FR (1) | FR14C0028I2 (hu) |
HK (1) | HK1066479A1 (hu) |
HU (2) | HU228508B1 (hu) |
IL (2) | IL160595A0 (hu) |
LU (1) | LU92439I2 (hu) |
MX (1) | MXPA04002405A (hu) |
MY (1) | MY129422A (hu) |
NO (2) | NO333813B1 (hu) |
NZ (1) | NZ531651A (hu) |
PL (2) | PL393155A1 (hu) |
PT (2) | PT2042168E (hu) |
RU (2) | RU2312854C2 (hu) |
SI (2) | SI2042168T1 (hu) |
TW (1) | TWI299661B (hu) |
WO (1) | WO2003024439A1 (hu) |
Families Citing this family (167)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6759398B2 (en) * | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
ATE417606T1 (de) * | 2001-09-14 | 2009-01-15 | Glaxo Group Ltd | Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege |
WO2003024396A2 (en) | 2001-09-17 | 2003-03-27 | Glaxo Group Limited | Dry powder medicament formulations |
TWI249515B (en) * | 2001-11-13 | 2006-02-21 | Theravance Inc | Aryl aniline beta2 adrenergic receptor agonists |
JP2005527618A (ja) | 2002-05-28 | 2005-09-15 | セラヴァンス インコーポレーテッド | アルコキシアリールβ2アドレナリン作動性レセプターアゴニスト |
GB0220730D0 (en) * | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
AR041724A1 (es) | 2002-10-28 | 2005-05-26 | Glaxo Group Ltd | Compuestos derivados de fenetanolamina y su utilizacion en composiciones farmaceuticas |
PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
GB0303396D0 (en) * | 2003-02-14 | 2003-03-19 | Glaxo Group Ltd | Medicinal compounds |
DE602004024383D1 (de) | 2003-05-08 | 2010-01-14 | Theravance Inc | Kristalline formen eines arylanilin-beta-2-adrenergenrezeptor-agonists |
TW200510277A (en) | 2003-05-27 | 2005-03-16 | Theravance Inc | Crystalline form of β2-adrenergic receptor agonist |
US7067541B2 (en) | 2003-06-04 | 2006-06-27 | Pfizer Inc | 2-amino-pyridine derivatives useful for the treatment of diseases |
BRPI0410660A (pt) * | 2003-06-04 | 2006-06-20 | Pfizer | derivados de 2-amino-piridina como agonistas de adrenoreceptor ß2 |
GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
TW200526547A (en) | 2003-09-22 | 2005-08-16 | Theravance Inc | Amino-substituted ethylamino β2 adrenergic receptor agonists |
GB0329182D0 (en) * | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Chemical compounds |
TW200531692A (en) | 2004-01-12 | 2005-10-01 | Theravance Inc | Aryl aniline derivatives as β2 adrenergic receptor agonists |
GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
TWI341836B (en) | 2004-03-11 | 2011-05-11 | Theravance Inc | Biphenyl compounds useful as muscarinic receptor antagonists |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
PE20060272A1 (es) | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
CN1984876A (zh) | 2004-06-03 | 2007-06-20 | 施万制药 | 二胺类β2肾上腺素能受体激动剂 |
TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
JP2008507532A (ja) | 2004-07-21 | 2008-03-13 | セラヴァンス, インコーポレーテッド | ジアリールエーテルβ2アドレナリン作用性レセプターアゴニスト |
GB0418045D0 (en) | 2004-08-12 | 2004-09-15 | Glaxo Group Ltd | Compounds |
EP1833822A2 (en) | 2004-08-16 | 2007-09-19 | Theravance, Inc. | Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
EP1786762A2 (en) * | 2004-09-10 | 2007-05-23 | Theravance, Inc. | Amidine substituted aryl aniline compounds |
GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
EP1841780B1 (en) | 2005-01-10 | 2011-07-27 | Glaxo Group Limited | Androstane 17-alpha-carbonate derivatives for use in the treatment of allergic and inflammatory conditions |
TWI389690B (zh) | 2005-03-25 | 2013-03-21 | Glaxo Group Ltd | 新穎化合物(一) |
GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
EP2281813A1 (en) | 2005-08-08 | 2011-02-09 | Pulmagen Therapeutics (Synergy) Limited | Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses |
GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
TW200738658A (en) | 2005-08-09 | 2007-10-16 | Astrazeneca Ab | Novel compounds |
GB0520794D0 (en) * | 2005-10-12 | 2005-11-23 | Innovata Biomed Ltd | Inhaler |
JP5006330B2 (ja) | 2005-10-21 | 2012-08-22 | ノバルティス アーゲー | Il13に対するヒト抗体および治療的使用 |
TW200730498A (en) | 2005-12-20 | 2007-08-16 | Glaxo Group Ltd | Compounds |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
TW200745067A (en) | 2006-03-14 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
US7943651B2 (en) | 2006-04-20 | 2011-05-17 | Glaxo Group Limited | Compounds |
ES2384337T3 (es) | 2006-04-21 | 2012-07-03 | Novartis Ag | Derivados de purina para su uso como agonistas del receptor de adenosina A2A |
GB0611587D0 (en) | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
CL2007001829A1 (es) | 2006-06-23 | 2008-01-25 | Smithkline Beecham Corp | P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc. |
SI2046787T1 (sl) | 2006-08-01 | 2011-07-29 | Glaxo Group Ltd | Pirazolo(3,4-b)piridinske spojine in njihova uporaba kot PDE4 inhibitorji |
TW200833670A (en) | 2006-12-20 | 2008-08-16 | Astrazeneca Ab | Novel compounds 569 |
BRPI0720799A2 (pt) | 2007-01-10 | 2014-03-11 | Irm Llc | Compostos e composições como inibidores de protease de ativação de canal. |
GB0702458D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | Salts 668 |
CA2677485A1 (en) | 2007-02-09 | 2008-08-14 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
AR065804A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
JP5244904B2 (ja) | 2007-05-07 | 2013-07-24 | ノバルティス アーゲー | 有機化合物 |
EA017919B1 (ru) | 2007-12-10 | 2013-04-30 | Новартис Аг | Производные пиразин-2-карбоксамида для лечения заболеваний, которые поддаются лечению путем блокирования эпителиальных натриевых каналов |
US8431578B2 (en) | 2008-01-11 | 2013-04-30 | Novartis Ag | Organic compounds |
EP2096105A1 (en) * | 2008-02-28 | 2009-09-02 | Laboratorios Almirall, S.A. | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor |
MX2010012814A (es) | 2008-05-23 | 2010-12-20 | Amira Pharmaceuticals Inc | Inhibidor de proteina activadora de 5-lipoxigenasa. |
ES2566339T3 (es) | 2008-06-05 | 2016-04-12 | Glaxo Group Limited | Derivados de 4-carboxamida indazol útiles como inhibidores de PI3-quinasas |
CA2727196A1 (en) | 2008-06-10 | 2009-12-17 | Novartis Ag | Organic compounds |
EA201001747A1 (ru) | 2008-06-18 | 2011-08-30 | Астразенека Аб | Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств |
US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
ES2442343T3 (es) | 2008-12-30 | 2014-02-11 | Pulmagen Therapeutics (Inflammation) Limited | Compuestos de sulfonamida para el tratamiento de trastornos respiratorios |
WO2010094643A1 (en) | 2009-02-17 | 2010-08-26 | Glaxo Group Limited | Quinoline derivatives and their uses for rhinitis and urticaria |
WO2010097114A1 (en) * | 2009-02-26 | 2010-09-02 | Glaxo Group Limited | Novel combination of therapeutic agents |
EP2400950B1 (en) * | 2009-02-26 | 2019-05-22 | Glaxo Group Limited | Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol |
WO2010102958A1 (en) | 2009-03-09 | 2010-09-16 | Glaxo Group Limited | 4-oxadiazol-2 -yl- indazoles as inhibitors of p13 kinases |
EP2406249A1 (en) | 2009-03-10 | 2012-01-18 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
WO2010106016A1 (en) | 2009-03-17 | 2010-09-23 | Glaxo Group Limited | Pyrimidine derivatives used as itk inhibitors |
EP2408916A2 (en) | 2009-03-19 | 2012-01-25 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
EP2408915A2 (en) | 2009-03-19 | 2012-01-25 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
MX2011009724A (es) | 2009-03-19 | 2011-10-14 | Merck Sharp & Dohme | Inhibicion mediada por interferencia de acido ribonucleico de la expresion del gen del factor de transcripcion basico de cierre de leucina 1 de homologia de btb y cnc 1, usando el listado de secuencias de acido nucleico corto de interferencia. |
EP2408458A1 (en) | 2009-03-19 | 2012-01-25 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20120004281A1 (en) | 2009-03-27 | 2012-01-05 | Merck Sharp & Dohme Corp | RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
JP2012521765A (ja) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸(siNA)を用いた細胞内接着分子1(ICAM−1)遺伝子発現のRNA干渉媒介性阻害 |
EP2411520A2 (en) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010111471A2 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010111464A1 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
US20100273744A1 (en) | 2009-04-24 | 2010-10-28 | Paul Martin Gore | Compounds |
WO2010122088A1 (en) | 2009-04-24 | 2010-10-28 | Glaxo Group Limited | Pyrazole and triazole carboxamides as crac channel inhibitors |
BRPI1016219B8 (pt) | 2009-04-30 | 2021-05-25 | Glaxo Group Ltd | composto indazol substituído com oxazol, e, composição farmacêutica |
WO2010150014A1 (en) | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | 5r- 5 -deuterated glitazones for respiratory disease treatment |
SG178036A1 (en) | 2009-07-15 | 2012-03-29 | Theravance Inc | Crystalline freebase forms of a biphenyl compound |
US20110098311A1 (en) | 2009-10-22 | 2011-04-28 | Vertex Pharmaceuticals Incorported | Compositions for treatment of cystic fibrosis and other chronic diseases |
GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
GB0921075D0 (en) * | 2009-12-01 | 2010-01-13 | Glaxo Group Ltd | Novel combination of the therapeutic agents |
WO2011067364A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Novel compounds |
JP2013512879A (ja) | 2009-12-03 | 2013-04-18 | グラクソ グループ リミテッド | Pi3キナーゼの阻害剤としてのベンズピラゾール誘導体 |
WO2011067366A1 (en) | 2009-12-03 | 2011-06-09 | Glaxo Group Limited | Indazole derivatives as pi 3 - kinase inhibitors |
EP2512438B1 (en) | 2009-12-16 | 2017-01-25 | 3M Innovative Properties Company | Formulations and methods for controlling mdi particle size delivery |
WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
GB201002243D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
GB201002224D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
WO2011110575A1 (en) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
KR101004750B1 (ko) * | 2010-08-16 | 2011-01-04 | 주식회사 행림종합 건축사사무소 | 피막보호형 보강 단열패널 및 이를 이용한 노출형 외단열방수공법 |
AU2014268195B2 (en) * | 2010-08-31 | 2015-11-12 | Glaxo Group Limited | Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
WO2012028663A1 (en) * | 2010-08-31 | 2012-03-08 | Glaxo Group Limited | Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same |
PL2614058T3 (pl) | 2010-09-08 | 2015-12-31 | Glaxosmithkline Ip Dev Ltd | Polimorfy i sole n-[5-[4-(5-{[(2r,6s)-2,6-dimetylo-4-morfolinylo]-metylo}-1,3-oksazol-2-ilo)-1h-indazol-6-ilo]-2-(metyloksy)-3-pirydynylo]metanosulfonamidu |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
WO2012035055A1 (en) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
GB201016912D0 (en) | 2010-10-07 | 2010-11-24 | Astrazeneca Ab | Novel combination |
WO2012052459A1 (en) | 2010-10-21 | 2012-04-26 | Glaxo Group Limited | Pyrazole compounds acting against allergic, inflammatory and immune disorders |
ES2532213T3 (es) | 2010-10-21 | 2015-03-25 | Glaxo Group Limited | Compuestos de pirazol que actúan contra afecciones alérgicas, inmunitarias e inflamatorias |
GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
EP2675439A2 (en) | 2011-02-17 | 2013-12-25 | Cipla Limited | Combination of glycopyrrolate and a beta2 -agonist |
WO2012116217A1 (en) | 2011-02-25 | 2012-08-30 | Irm Llc | Compounds and compositions as trk inhibitors |
GB201104153D0 (en) | 2011-03-11 | 2011-04-27 | Glaxo Group Ltd | Novel compounds |
EP2683716A1 (en) | 2011-03-11 | 2014-01-15 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
CN103561731A (zh) | 2011-06-08 | 2014-02-05 | 葛兰素集团有限公司 | 包含芜地溴铵的干粉吸入器组合物 |
US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
CN103946221B (zh) | 2011-09-16 | 2016-08-03 | 诺华股份有限公司 | 用于治疗囊性纤维化的杂环化合物 |
ES2882807T3 (es) | 2011-09-16 | 2021-12-02 | Novartis Ag | Heterociclil carboxamidas N-sustituidas |
GB201116641D0 (en) | 2011-09-27 | 2011-11-09 | Glaxo Group Ltd | Novel compounds |
US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
RU2666963C2 (ru) | 2012-04-13 | 2018-09-13 | Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Агрегированные частицы |
TWI593678B (zh) | 2012-04-27 | 2017-08-01 | 葛蘭素集團有限公司 | 作為類視色素相關孤兒受體γ(RORγ)調節劑之化合物、其醫藥組合物及用途 |
GB201207406D0 (en) | 2012-04-27 | 2012-06-13 | Glaxo Group Ltd | Novel compounds |
UA115989C2 (uk) | 2012-07-05 | 2018-01-25 | Арвен Айлак Санайі Ве Тіджарет А.С. | Фармацевтична композиція для інгалятора сухого порошку, що містить антагоністи мускаринових рецепторів тривалої дії |
US20150239862A1 (en) * | 2012-09-13 | 2015-08-27 | Perrigo Api Ltd. | Process for the preparation of vilanterol and intermediates thereof |
GB201222679D0 (en) | 2012-12-17 | 2013-01-30 | Glaxo Group Ltd | Pharmaceutical combination products |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
PL2968313T3 (pl) | 2013-03-15 | 2018-07-31 | Verona Pharma Plc | Kombinacja leków |
WO2015055690A1 (en) | 2013-10-17 | 2015-04-23 | Glaxosmithkline Intellectual Property Development Limited | Pi3k inhibitor for treatment of respiratory disease |
KR20160062178A (ko) | 2013-10-17 | 2016-06-01 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 호흡기 질병의 치료를 위한 pi3k 억제제 |
CN104744270A (zh) * | 2013-12-26 | 2015-07-01 | 成都伊诺达博医药科技有限公司 | 长效β2受体激动剂维兰特罗的合成新方法 |
CN104744271B (zh) * | 2013-12-26 | 2016-08-31 | 成都伊诺达博医药科技有限公司 | 一种合成维兰特罗的新工艺 |
MX2016013983A (es) | 2014-04-24 | 2017-04-06 | Novartis Ag | Derivados de pirazina como inhibidores de fosfatidil-inositol-3-ci nasa. |
BR112016024484A2 (pt) | 2014-04-24 | 2017-08-15 | Novartis Ag | derivados de aminopiridina como inibidores de fosfatidilinositol 3-quinase |
BR112016024533A8 (pt) | 2014-04-24 | 2021-03-30 | Novartis Ag | derivados de amino pirazina como inibidores de fosfatidilinositol 3-cinase ou sal, seu uso, e composição e combinação farmacêuticas |
WO2015173701A2 (en) | 2014-05-12 | 2015-11-19 | Glaxosmithkline Intellectual Property (No. 2) Limited | Pharmaceutical compositions for treating infectious diseases |
EP3650019B8 (en) | 2014-05-28 | 2023-10-11 | GlaxoSmithKline Intellectual Property Development Limited | Fluticasone furoate in the treatment of copd |
EP2957553A1 (en) | 2014-06-16 | 2015-12-23 | Arven Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical formulations of vilanterol |
EP2957552B1 (en) | 2014-06-16 | 2020-01-22 | Arven Ilac Sanayi Ve Ticaret A.S. | Vilanterol formulations |
EP2957550A1 (en) | 2014-06-16 | 2015-12-23 | Arven Ilac Sanayi Ve Ticaret A.S. | Pharmaceutical formulations comprising vilanterol |
TR201407010A2 (tr) | 2014-06-16 | 2015-12-21 | Arven Ilac Sanayi Ve Ticaret Anonim Sirketi | Vilanterol formülasyonları. |
EP3166592A1 (en) | 2014-07-09 | 2017-05-17 | Arven Ilac Sanayi Ve Ticaret A.S. | A process for the preparation of dry powder formulations |
PT3166594T (pt) | 2014-07-09 | 2018-06-06 | Arven Ilac Sanayi Ve Ticaret As | Processo para preparar as formulações de inalação |
WO2016005443A1 (en) | 2014-07-09 | 2016-01-14 | Arven Ilac Sanayi Ve Ticaret A.S. | A process for the preparation of formulations for inhalation |
WO2017001907A1 (en) | 2015-06-29 | 2017-01-05 | Teva Pharmaceuticals International Gmbh | Biocatalytic processes for the preparation of vilanterol |
GB201602527D0 (en) | 2016-02-12 | 2016-03-30 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
CN107188813B (zh) * | 2016-03-14 | 2019-04-26 | 益方生物科技(上海)有限公司 | 苯乙醇胺衍生物及其制备方法和用途 |
JP2019524792A (ja) | 2016-08-08 | 2019-09-05 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 化合物 |
GB201706102D0 (en) | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
PT110209B (pt) * | 2017-07-19 | 2021-05-17 | Hovione Farm Sa | Formas polimórficas de trifenatato de vilanterol e processos para a preparação das mesmas. |
GB201712081D0 (en) | 2017-07-27 | 2017-09-13 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
WO2019176425A1 (ja) | 2018-03-14 | 2019-09-19 | 旭化成株式会社 | スルホン酸基含有モノマーの製造方法 |
IT201800004492A1 (it) * | 2018-04-13 | 2019-10-13 | Procedimento per la sintesi di beta-amminoalcoli otticamente attivi | |
US11484531B2 (en) | 2018-08-30 | 2022-11-01 | Theravance Biopharma R&D Ip, Llc | Methods for treating chronic obstructive pulmonary disease |
CN109574861A (zh) * | 2019-01-22 | 2019-04-05 | 安徽德信佳生物医药有限公司 | 一种维兰特罗三苯乙酸盐的结晶方法 |
CN111807973B (zh) * | 2019-04-10 | 2021-04-30 | 上海谷森医药有限公司 | 维兰特罗及其盐的制备方法 |
US11642333B2 (en) | 2019-05-23 | 2023-05-09 | Anovent Pharmaceutical (U.S.), Llc | Inhalable formulation of a solution containing vilanterol trifenatate and umeclidinium bromide |
MX2021015133A (es) | 2019-06-10 | 2022-01-24 | Novartis Ag | Derivado de piridina y pirazina para el tratamiento de la fibrosis quistica, enfermedad pulmonar obstructiva cronica y bronquiectasia. |
US20220306617A1 (en) | 2019-08-28 | 2022-09-29 | Novartis Ag | Substituted 1,3-phenyl heteroaryl derivatives and their use in the treatment of disease |
CN114126600B (zh) | 2020-01-20 | 2024-03-08 | 广州谷森制药有限公司 | 三苯乙酸维兰特罗的脂质体制剂 |
US20230286898A1 (en) | 2020-07-27 | 2023-09-14 | Inke, S.A. | Method for the purification of vilanterol trifenatate |
WO2023118833A1 (en) | 2021-12-22 | 2023-06-29 | Hovione Scientia Limited | Process to prepare vilanterol trifenatate |
CN115286491B (zh) * | 2022-08-31 | 2023-09-15 | 山东省药学科学院 | 一种2-[2-(6-溴己氧基)乙氧基甲基]-1,3-二氯苯的制备方法 |
CN115745945A (zh) * | 2022-11-15 | 2023-03-07 | 奥锐特药业股份有限公司 | 一锅法制备维兰特罗中间体的方法 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2140800A (en) * | 1937-04-26 | 1938-12-20 | Metallurg De Hoboken Soc Gen | Treatment of substances containing tantalum and/or niobium |
US2918408A (en) | 1957-04-08 | 1959-12-22 | Lakeside Lab Inc | Anti-spasmodic compositions specific for treating spasm of the colon |
DE2140800C3 (de) | 1971-08-14 | 1980-10-16 | Industriewerk Schaeffler Ohg, 8522 Herzogenaurach | Loswalze für Streckwerke von Spinnmaschinen |
US3994974A (en) * | 1972-02-05 | 1976-11-30 | Yamanouchi Pharmaceutical Co., Ltd. | α-Aminomethylbenzyl alcohol derivatives |
CY1308A (en) | 1979-12-06 | 1985-12-06 | Glaxo Group Ltd | Device for dispensing medicaments |
DE3274065D1 (de) | 1981-07-08 | 1986-12-11 | Draco Ab | Powder inhalator |
CA1224992A (en) | 1982-10-08 | 1987-08-04 | Robert E. Newell | Device for administering medicament to patients |
GB2169265B (en) | 1982-10-08 | 1987-08-12 | Glaxo Group Ltd | Pack for medicament |
ZW6584A1 (en) | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
US4853381A (en) | 1984-04-17 | 1989-08-01 | Glaxo Group Limited | Ethanolamine compounds |
KR850007422A (ko) | 1984-04-17 | 1985-12-04 | 원본미기재 | 펜에탄올아민 화합물의 제조방법 |
DK173685A (da) | 1984-04-17 | 1985-10-18 | Glaxo Group Ltd | Ethanolaminderivater |
GB8426200D0 (en) * | 1984-10-17 | 1984-11-21 | Glaxo Holdings Ltd | Chemical compounds |
DE3524990A1 (de) | 1984-07-13 | 1986-01-23 | Glaxo Group Ltd., London | Aminophenolverbindungen, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zubereitungen |
FR2585563B1 (fr) | 1985-07-30 | 1993-11-12 | Glaxo Group Ltd | Dispositif pour administrer des medicaments a des patients |
FR2588474B1 (fr) | 1985-10-16 | 1987-11-27 | Cird | Compositions synergetiques anti-inflammatoires a base d'un corticosteroide et d'un beta agoniste |
GB8525483D0 (en) | 1985-10-16 | 1985-11-20 | Glaxo Group Ltd | Chemical compounds |
EP0223410A3 (en) | 1985-10-16 | 1987-11-19 | Glaxo Group Limited | Ethanolamine derivatives |
EP0220054A3 (en) | 1985-10-16 | 1987-12-02 | Glaxo Group Limited | Ethanolamine derivatives |
US4937268A (en) * | 1987-03-12 | 1990-06-26 | Glaxo Group Limited | Chemical compounds |
GB8718940D0 (en) | 1987-08-11 | 1987-09-16 | Glaxo Group Ltd | Chemical compounds |
JPH0228141A (ja) | 1987-11-13 | 1990-01-30 | Glaxo Group Ltd | フェネタノールアミン誘導体 |
GB8821179D0 (en) * | 1988-09-09 | 1988-10-12 | Glaxo Group Ltd | Chemical compounds |
GB2230523A (en) | 1989-04-14 | 1990-10-24 | Glaxo Group Ltd | 1-(3-Bromoisoxazol-5-yl)-2-aminoethanol derivatives |
GB8909273D0 (en) | 1989-04-24 | 1989-06-07 | Glaxo Group Ltd | Chemical compounds |
US5290815A (en) | 1989-09-07 | 1994-03-01 | Glaxo Group Limited | Treatment of inflammation and allergy |
IL95590A (en) | 1989-09-08 | 1996-06-18 | Glaxo Group Ltd | Medicinal preparations containing Salmetrol and Pluticasone Propionate |
GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
DE4028398A1 (de) | 1990-09-07 | 1992-03-12 | Thomae Gmbh Dr K | Phenylethanolamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
CZ283425B6 (cs) | 1992-04-02 | 1998-04-15 | Smithkline Beecham Corporation | Fenylové deriváty a farmaceutické prostředky s jejich obsahem |
GB9222700D0 (en) | 1992-10-29 | 1992-12-09 | Smithkline Beecham Plc | Chemical compounds |
GB9313574D0 (en) | 1993-07-01 | 1993-08-18 | Glaxo Group Ltd | Medicaments |
GB9323429D0 (en) | 1993-11-12 | 1994-01-05 | Wellcome Found | Therapy |
WO1995019336A1 (de) | 1994-01-12 | 1995-07-20 | Iovis Biomedical And Pharmaceutical Consultants | Phenylethanolaminether und ihre verwendung als beta-adrenorezeptor-agonisten |
US5998428A (en) * | 1995-05-31 | 1999-12-07 | Smithkline Beecham Corporation | Compounds and methods for treating PDE IV-related diseases |
AU4967997A (en) | 1996-12-02 | 1998-06-29 | Chisso Corporation | Optically active nitro alcohol derivatives, optically active amino alcohol derivates, and process for preparing the same |
AU9281298A (en) | 1997-10-01 | 1999-04-23 | Kyowa Hakko Kogyo Co. Ltd. | Benzodioxole derivatives |
EP1070056B1 (en) | 1998-03-14 | 2004-06-30 | ALTANA Pharma AG | Phthalazinone pde iii/iv inhibitors |
AR035987A1 (es) | 1999-03-01 | 2004-08-04 | Smithkline Beecham Corp | Uso de un compuesto inhibidor de la pde 4 para la manufactura de un medicamento y el medicamento para tratar asma inducida por ejercicio |
ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
PL200923B1 (pl) | 1999-08-21 | 2009-02-27 | Nycomed Gmbh | Lek zawierający inhibitor PDE w połączeniu z agonistą receptoraß₂ -adrenergicznego oraz zastosowanie połączenia roflumilastu i salmeterolu |
GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
EP1366025B1 (en) | 2001-03-08 | 2007-06-27 | Glaxo Group Limited | Agonists of beta-adrenoreceptors |
ATE417606T1 (de) | 2001-09-14 | 2009-01-15 | Glaxo Group Ltd | Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege |
GB0303396D0 (en) | 2003-02-14 | 2003-03-19 | Glaxo Group Ltd | Medicinal compounds |
US7351787B2 (en) * | 2004-03-05 | 2008-04-01 | Bioartificial Gel Technologies, Inc. | Process for the preparation of activated polyethylene glycols |
-
2002
- 2002-09-11 AT AT02760407T patent/ATE417606T1/de active
- 2002-09-11 CN CN200910208840.6A patent/CN101701006B/zh not_active Expired - Lifetime
- 2002-09-11 ES ES08170993.3T patent/ES2438985T3/es not_active Expired - Lifetime
- 2002-09-11 WO PCT/GB2002/004140 patent/WO2003024439A1/en active Application Filing
- 2002-09-11 JP JP2003528536A patent/JP4191034B2/ja not_active Expired - Lifetime
- 2002-09-11 HU HU0401619A patent/HU228508B1/hu active Protection Beyond IP Right Term
- 2002-09-11 SI SI200231039T patent/SI2042168T1/sl unknown
- 2002-09-11 PT PT81709933T patent/PT2042168E/pt unknown
- 2002-09-11 SI SI200230795T patent/SI1425001T1/sl unknown
- 2002-09-11 RU RU2004106555/04A patent/RU2312854C2/ru active Protection Beyond IP Right Term
- 2002-09-11 CN CN201310042387.2A patent/CN103288793B/zh not_active Expired - Lifetime
- 2002-09-11 KR KR1020097010537A patent/KR20090057477A/ko not_active Application Discontinuation
- 2002-09-11 MX MXPA04002405A patent/MXPA04002405A/es active IP Right Grant
- 2002-09-11 PL PL393155A patent/PL393155A1/pl not_active Application Discontinuation
- 2002-09-11 DE DE60230425T patent/DE60230425D1/de not_active Expired - Lifetime
- 2002-09-11 US US13/719,797 patent/USRE44874E1/en not_active Expired - Lifetime
- 2002-09-11 AU AU2002326026A patent/AU2002326026B2/en active Active
- 2002-09-11 BR BRPI0212455A patent/BRPI0212455B8/pt not_active IP Right Cessation
- 2002-09-11 PL PL370276A patent/PL211953B1/pl not_active IP Right Cessation
- 2002-09-11 ES ES02760407T patent/ES2316599T3/es not_active Expired - Lifetime
- 2002-09-11 EP EP08170993.3A patent/EP2042168B1/en not_active Expired - Lifetime
- 2002-09-11 CA CA2458534A patent/CA2458534C/en not_active Expired - Lifetime
- 2002-09-11 CN CN02822325XA patent/CN1585633B/zh not_active Expired - Lifetime
- 2002-09-11 IL IL16059502A patent/IL160595A0/xx unknown
- 2002-09-11 NZ NZ531651A patent/NZ531651A/en not_active IP Right Cessation
- 2002-09-11 EP EP02760407A patent/EP1425001B1/en not_active Expired - Lifetime
- 2002-09-11 US US10/489,569 patent/US7361787B2/en not_active Ceased
- 2002-09-11 PT PT02760407T patent/PT1425001E/pt unknown
- 2002-09-11 DK DK08170993.3T patent/DK2042168T3/da active
- 2002-09-11 DK DK02760407T patent/DK1425001T3/da active
- 2002-09-11 KR KR1020047003795A patent/KR100912324B1/ko active Protection Beyond IP Right Term
- 2002-09-12 MY MYPI20023401A patent/MY129422A/en unknown
- 2002-09-12 TW TW091120875A patent/TWI299661B/zh active
- 2002-09-13 AR ARP020103476A patent/AR036874A1/es active IP Right Grant
-
2004
- 2004-02-26 IL IL160595A patent/IL160595A/en active Protection Beyond IP Right Term
- 2004-03-10 CO CO04021965A patent/CO5560552A2/es active IP Right Grant
- 2004-03-11 NO NO20041041A patent/NO333813B1/no not_active IP Right Cessation
- 2004-11-30 HK HK04109440.3A patent/HK1066479A1/xx not_active IP Right Cessation
-
2006
- 2006-12-04 US US11/566,346 patent/US7439393B2/en active Active
-
2007
- 2007-06-28 RU RU2007124187/04A patent/RU2007124187A/ru not_active Application Discontinuation
-
2008
- 2008-09-16 US US12/211,322 patent/US7776895B2/en not_active Expired - Lifetime
-
2009
- 2009-02-25 CY CY20091100211T patent/CY1109422T1/el unknown
-
2010
- 2010-07-14 US US12/836,025 patent/US7982067B2/en not_active Expired - Lifetime
-
2011
- 2011-06-21 US US13/165,037 patent/US8198483B2/en not_active Expired - Lifetime
-
2013
- 2013-06-27 AR ARP130102285 patent/AR091595A2/es not_active Application Discontinuation
- 2013-12-16 CY CY20131101131T patent/CY1114728T1/el unknown
-
2014
- 2014-04-02 FR FR14C0028C patent/FR14C0028I2/fr active Active
- 2014-04-03 NO NO2014007C patent/NO2014007I1/no not_active IP Right Cessation
- 2014-04-24 HU HUS1400025C patent/HUS1400025I1/hu unknown
- 2014-04-25 BE BE2014C026C patent/BE2014C026I2/fr unknown
- 2014-04-28 CY CY2014019C patent/CY2014019I1/el unknown
- 2014-04-30 LU LU92439C patent/LU92439I2/fr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0401619A2 (hu) | Fenilanolamin-származékok, eljárás előállításukra, és az ezeket tartalmazó gyógyszerkészítmények | |
AR003936A1 (es) | Compuestos triciclicos y composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de un medicamento util para inhibir elcrecimiento anormal de celulas. | |
HUP0102094A2 (hu) | Biciklusos hidroxámsav-származékok | |
HUP0400699A2 (hu) | Fenetanolaminszármazékok, eljárás előállításukra és ilyen vegyületeket tartalmazó gyógyszerkészítmények | |
EP2308845A3 (en) | Caspase inhibitors and uses thereof | |
CA2155673A1 (en) | N-alkyl-2-substituted atp analogues | |
HUP0300340A2 (hu) | c-JUN N-terminális kinázok (JNK) és más protein kinázok inhibitorai, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
HUP0300741A2 (hu) | Biciklopirazolok mint kináz inhibitorok, előállítási eljárásuk és a vegyületeket tartalmazó gyógyszerkészítmények | |
HUP0103460A2 (hu) | Vírusellenes hatású indolszármazékok és a vegyületeket tartalmazó gyógyszerkészítmények | |
HUP0300922A2 (hu) | Új vegyületek, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
TR200102911T2 (tr) | Adamantan türevleri. | |
CA2529347A1 (en) | Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections | |
HUP0402227A2 (hu) | Fenil-szubsztituált triazolok és az AKL5 kináz szelektív inhibitoraiként történő felhasználásuk és a vegyületeket tartalmazó gyógyszerkészítmények | |
HUP0402019A2 (hu) | CCR5 antagonistaként alkalmazható piperidinszármazékok és ezeket tartalmazó gyógyszerkészítmények | |
HUP0203054A2 (hu) | Farnezil protein transzferáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
NO20054092L (no) | Nye tricykliske azepinforbindelser, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger inneholdende dem | |
HUP0201722A2 (hu) | Gyógyászati készítmények alkoholizmus és alkoholfüggőség kezelésére | |
TR200000616T2 (tr) | Tetrahidro gamma karbolinler. | |
HUP0402028A2 (hu) | Telítetlen 1-amino-alkilciklohexán-származékok az ezeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
HRP20070030T3 (en) | Derivatives of benzothiazine and benzothiadiazine, procedure for their preparation and pharmaceutical compositions containing them | |
HUP0002929A2 (hu) | Tachikinin receptor antagonista hatású 2-acilamino-propán-aminok és az ezeket tartalmazó gyógyszerkészítmények | |
HUP0004704A2 (hu) | Dihidrofuro[3,4-b]kinolin-1-on-származékok, eljárás ezek előállítására és ezeket tartalmazó gyógyászati készítmények | |
HUP0401562A2 (hu) | Kinolinszármazékok és alkalmazásuk tumorellenes szerekként és ezeket tartalmazó gyógyászati készítmények | |
HUP0202379A2 (hu) | Új vegyületek, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények | |
HUP0303127A2 (hu) | Új heterociklusos-vagy benzol-liponsav-származékok, ezek előállítása és gyógyszerként való alkalmazásuk |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC9A | Change of name, address |
Owner name: GLAXO GROUP LIMITED, GB Free format text: FORMER OWNER(S): GLAXO GROUP LIMITED, GB |
|
AA1S | Information on application for a supplementary protection certificate |
Free format text: PRODUCT NAME: VILANTEROL OR A SALT OR SOLVATE THEREOF VILANTEROL TRIFENATATE; REG. NO/DATE: EU/1/13/886/001-006 20131113 Spc suppl protection certif: S1400025 Filing date: 20140424 Expiry date: 20220911 |
|
FG4S | Grant of supplementary protection certificate |
Free format text: PRODUCT NAME: VILANTEROL OR A SALT OR SOLVATE THEREOF; REGISTRATION NO/DATE: EU/1/13/886/001-006 20131114 Spc suppl protection certif: S1400025 Filing date: 20140424 Expiry date: 20220911 Extension date: 20270911 |